UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Unless the context otherwise requires, in this exhibit, the terms “Sonoco” and the “Company” refer to Sonoco Products Company, a South Carolina corporation, and its consolidated subsidiaries, and the term “Eviosys” refers to Titan Holdings I B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, and its subsidiaries. All capitalized terms used but not defined herein that are defined and included in the Current Report on Form 8-K to which this exhibit is attached (the “Current Report”) shall have the same meanings assigned to them in the Current Report.
Introduction
The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X to reflect the probable acquisition of the entire equity interest of Eviosys by Sonoco (the “Eviosys Acquisition”) pursuant to the Equity Purchase Agreement, dated June 22, 2024, by and among Titan Holdings Coöperatief U.A., a cooperative with excluded liability (coöperatie met uitgesloten aansprakelijkheid), incorporated under the laws of the Netherlands (the “Seller”), Eviosys and Sonoco (the “Purchase Agreement”) and the related financing transactions. As described in more detail in Note 2 below, the Company expects to fund the cash consideration payable by the Company in connection with the Eviosys Acquisition, including related fees and expenses, with the net proceeds from the issuance and sale of senior unsecured notes, borrowings under its Acquisition Term Loan Facilities (as defined in Note 2. Description of Financing) and cash on hand or additional borrowings under its existing $1.25 billion revolving credit facility (“Revolving Credit Facility”).
The unaudited pro forma condensed combined balance sheet combines the historical unaudited condensed consolidated balance sheet of Sonoco as of June 30, 2024 and the historical unaudited condensed consolidated balance sheet of Eviosys as of June 30, 2024, giving effect to the Eviosys Acquisition and the related financing transactions as if they had been consummated on June 30, 2024.
The unaudited pro forma condensed combined statement of income for the six months ended June 30, 2024 combines the historical unaudited condensed consolidated statement of income of Sonoco for the six months ended June 30, 2024 and the historical unaudited condensed consolidated statement of income of Eviosys for the six months ended June 30, 2024. The unaudited pro forma condensed combined statement of income for the year ended December 31, 2023 combines the historical audited consolidated statement of income of Sonoco for the year ended December 31, 2023 and the historical audited consolidated statement of income of Eviosys for the year ended December 31, 2023. Both of the unaudited pro forma condensed combined statements of income give effect to the Eviosys Acquisition and the related financing transactions as if they had been consummated on January 1, 2023.
The unaudited pro forma condensed combined balance sheet and the unaudited pro forma condensed combined statements of income are collectively referred to as the “pro forma financial information.” The pro forma financial information is provided for illustrative purposes only and do not purport to represent the actual financial position and results of operations that would have been achieved had the Eviosys Acquisition and related financing transactions occurred on the dates indicated, and do not reflect adjustments for any anticipated integration costs, synergies, operating efficiencies, tax savings or cost savings. Actual amounts set forth in the pro forma financial information and in the accompanying notes are subject to adjustments and may differ at the time of the consummation of the Eviosys Acquisition and related financing transactions depending on several factors, including finalization of the transaction consideration in accordance with the terms of the Purchase Agreement, changes in the actual amount of fees and expenses related to the Eviosys Acquisition and the related financing transactions, changes in Sonoco’s financing plans, the outstanding amount of Sonoco indebtedness at that time, and the final purchase price allocation that will be completed following the closing of the Eviosys Acquisition. There can be no assurance that the Eviosys Acquisition or the related financing transactions will be consummated pursuant to the terms contemplated or at all. Even if the Eviosys Acquisition and the relating financing transactions are consummated, there can be no assurance as to when the closing of such transactions will take place. Further, the pro forma financial information does not purport to project the future operating results or financial position of Sonoco following the consummation of the Eviosys Acquisition and the related financing transactions.
The adjustments in the pro forma financial information have been identified and presented to provide an illustrative understanding of the effects of the Eviosys Acquisition and the anticipated financing transactions and have been prepared for informational purposes only. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date the pro forma financial information is issued and are subject to change as additional information becomes available and analyses are performed. There can be no assurance that additional information and analyses will not result in material changes. Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the pro forma financial information are described above and in the accompanying notes.
The pro forma financial information and the accompanying notes have been derived from and should be read in conjunction with:
• The following historical financial statements of Sonoco:
•The historical audited consolidated financial statements of Sonoco as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021, included in Sonoco’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2024 and incorporated herein by reference; and
•The historical unaudited condensed consolidated financial statements of Sonoco as of June 30, 2024 and December 31, 2023 and for the three and six months ended June 30, 2024 and July 2, 2023, included in Sonoco’s Quarterly Report on Form 10-Q filed with the SEC on August 1, 2024 and incorporated herein by reference.
• The following historical financial statements of Eviosys:
•The historical audited consolidated financial statements of Eviosys as of and for the years ended December 31, 2023 and 2022, which are included as Exhibit 99.1 to this Current Report; and
•The historical unaudited condensed consolidated financial statements of Eviosys as of June 30, 2024 and December 31, 2023 and for the six months ended June 30, 2024 and 2023, which are included as Exhibit 99.2 to this Current Report.
Sonoco Products Company
PRO FORMA CONDENSED COMBINED BALANCE SHEET
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
(Dollars and shares in thousands) as of June 30, 2024 | Sonoco | Eviosys (as Reclassified) (see Note 4) | IFRS to U.S. GAAP Adjustments | Note | Eviosys (U.S. GAAP) | Transaction Accounting Adjustments | Note | Pro Forma Condensed Combined |
Assets | | | | | | | | |
Current Assets | | | | | | | | |
Cash and cash equivalents | $ | 140,233 | | $ | 210,415 | | $ | — | | | $ | 210,415 | | $ | — | | 7A | $ | 350,648 | |
Trade accounts receivable, net | 960,262 | | 214,397 | | — | | | 214,397 | | (2,832) | | 7B | 1,171,827 | |
Other receivables | 109,575 | | 120,290 | | — | | | 120,290 | | — | | | 229,865 | |
Inventories | | | | | | | | |
Finished and in process | 341,952 | | 308,973 | | — | | | 308,973 | | 17,302 | | 7C | 668,227 | |
Materials and supplies | 390,621 | | 249,721 | | — | | | 249,721 | | (72,174) | | 7C | 568,168 | |
Prepaid expenses | 171,820 | | 39,858 | | — | | | 39,858 | | (10,088) | | 7D | 201,590 | |
Total Current Assets | 2,114,463 | | 1,143,654 | | — | | | 1,143,654 | | (67,792) | | | 3,190,325 | |
Property, Plant and Equipment, Net | 1,893,404 | | 882,891 | | — | | | 882,891 | | 190,496 | | 7E | 2,966,791 | |
Goodwill | 1,769,519 | | 885,486 | |
|
| 885,486 | | 268,887 | | 7F | 2,923,892 | |
Other Intangible Assets, Net | 803,911 | | 551,056 | | — | | | 551,056 | | 1,467,035 | | 7G | 2,822,002 | |
Long-term Deferred Income Taxes | 27,531 | | 23,725 | | — | | | 23,725 | | (12,821) | | 7H | 38,435 | |
Right of Use Asset-Operating Leases | 313,650 | | — | | 46,758 | | 3A | 46,758 | | — | | | 360,408 | |
Other Assets | 232,186 | | 37,816 | | (31,977) | | 3A,3C | 5,839 | | — | | | 238,025 | |
Total Assets | $ | 7,154,664 | | $ | 3,524,628 | | $ | 14,781 | | | $ | 3,539,409 | | $ | 1,845,805 | | | $ | 12,539,878 | |
Liabilities and Equity | | | | | | | | |
Current Liabilities | | | | | | | | |
Payable to suppliers | $ | 730,563 | | $ | 565,138 | | $ | — | | | $ | 565,138 | | $ | (2,832) | | 7I | $ | 1,292,869 | |
Accrued expenses and other | 402,758 | | 275,529 | | 15,561 | | 3A, 3C, 3D | 291,090 | | (20,724) | | 7J | 673,124 | |
Notes payable and current portion of long-term debt | 485,479 | | 13,361 | | (11,717) | | 3A | 1,644 | | 1,195,356 | | 7K | 1,682,479 | |
Accrued taxes | 7,333 | | 15,637 | | — | | | 15,637 | | — | | | 22,970 | |
Total Current Liabilities | 1,626,133 | | 869,665 | | 3,844 | | | 873,509 | | 1,171,800 | | | 3,671,442 | |
Long-term Debt | 2,541,929 | | 2,065,004 | | (8,364) | | 3A,3E | 2,056,640 | | 625,675 | | 7L | 5,224,244 | |
Noncurrent Operating Lease Liabilities | 267,493 | | — | | 33,519 | | 3A | 33,519 | | — | | | 301,012 | |
Pension and Other Postretirement Benefits | 140,011 | | 53,809 | | 826 | | 3C | 54,635 | | — | | | 194,646 | |
Deferred Income Taxes | 91,999 | | 215,876 | | 16 | | 3A, 3C, 3D | 215,892 | | 388,537 | | 7M | 696,428 | |
Other Liabilities | 45,232 | | 19,300 | | (2,388) | | 3D | 16,912 | | (2,275) | | 7N | 59,869 | |
Commitments and Contingencies | | | | | | | | |
Shareholders’ Equity | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Common shares, no par value | 7,175 | | — | | — | | | — | | — | | | 7,175 | |
| | | | | | | | |
| | | | | | | | |
Capital in excess of stated value | 167,114 | | 316,230 | | — | | | 316,230 | | (316,230) | | 7O | 167,114 | |
Accumulated other comprehensive loss | (418,317) | | 1,628 | | (16,133) | | 3C | (14,505) | | 14,505 | | 7D, 7P | (418,317) | |
Retained earnings | 2,678,673 | | (37,274) | | 3,461 | | 3A, 3C-3E | (33,813) | | (15,817) | | 7Q | 2,629,043 | |
Total Shareholders’ Equity | 2,434,645 | | 280,584 | | (12,672) | | | 267,912 | | (317,542) | | | 2,385,015 | |
Noncontrolling Interests | 7,222 | | 20,390 | | — | | | 20,390 | | (20,390) | | 7R | 7,222 | |
Total Equity | 2,441,867 | | 300,974 | | (12,672) | | | 288,302 | | (337,932) | | | 2,392,237 | |
Total Liabilities and Equity | $ | 7,154,664 | | $ | 3,524,628 | | $ | 14,781 | | | $ | 3,539,409 | | $ | 1,845,805 | | | $ | 12,539,878 | |
Sonoco Products Company
PRO FORMA CONDENSED COMBINED STATEMENT OF INCOME
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
(Dollars and shares in thousands except per share data) Six months ended June 30, 2024 | Sonoco | Eviosys (as Reclassified) (see Note 4) | IFRS to U.S. GAAP Adjustments | Note | Eviosys(U.S. GAAP) | Transaction Accounting Adjustments | Note | Pro Forma Condensed Combined |
Net sales | $ | 3,261,022 | | $ | 1,139,921 | | $ | — | | | $ | 1,139,921 | | $ | (7,917) | | 8A | $ | 4,393,026 | |
Cost of sales | 2,566,115 | | 953,061 | | 1,507 | | 3A-3D | 954,568 | | (12,234) | | 8A-8C, 8E | 3,508,449 | |
Gross profit | 694,907 | | 186,860 | | (1,507) | | | 185,353 | | 4,317 | | | 884,577 | |
Selling, general and administrative expenses | 395,692 | | 145,891 | | (1,926) | | 3A-3D | 143,965 | | 30,604 | | 8C, 8D, 8F-8G | 570,261 | |
Restructuring/Asset impairment charges | 50,868 | | 6,509 | | — | | | 6,509 | | — | | | 57,377 | |
Gain on divestiture of business and other assets
| 4,478 | | — | | — | | | — | | — | | | 4,478 | |
Operating profit | 252,825 | | 34,460 | | 419 | | | 34,879 | | (26,287) | | | 261,417 | |
Other income, net | 5,867 | | — | | — | | | — | | — | | | 5,867 | |
Non-operating pension costs | 7,465 | | 833 | | (9) | | 3C | 824 | | — | | | 8,289 | |
Interest expense | 60,860 | | 63,671 | | 11,975 | | 3A, 3E | 75,646 | | 15,389 | | 8H | 151,895 | |
Interest income | 7,113 | | 1,595 | | — | | | 1,595 | | — | | | 8,708 | |
Income/(Loss) before income taxes | 197,480 | | (28,449) | | (11,547) | | | (39,996) | | (41,676) | | | 115,808 | |
Provision for/(Benefit from) income taxes | 44,667 | | 4,687 | | (2,954) | | 3A-3E | 1,733 | | (16,327) | | 8I | 30,073 | |
Income/(Loss) before equity in earnings of affiliates | 152,813 | | (33,136) | | (8,593) | | | (41,729) | | (25,349) | | | 85,735 | |
Equity in earnings of affiliates, net of tax | 3,411 | | — | | — | | | — | | — | | | 3,411 | |
Net income/(loss) | 156,224 | | (33,136) | | (8,593) | | | (41,729) | | (25,349) | | | 89,146 | |
Net (income) attributable to noncontrolling interests | (236) | | (451) | | — | | | (451) | | — | | | (687) | |
Net income/(loss) attributable to Sonoco | $ | 155,988 | | $ | (33,587) | | $ | (8,593) | | | $ | (42,180) | | $ | (25,349) | | | $ | 88,459 | |
Weighted average common shares outstanding: | | | | | | | | |
Basic | 98,583 | | | | | | — | | | 98,583 | |
Assuming exercise of awards | 616 | | | | | | — | | | 616 | |
Diluted | 99,199 | | | | | | — | | | 99,199 | |
Per common share | | | | | | | | |
Net income attributable to Sonoco: | | | | | | | | |
Basic | $ | 1.58 | | | | | | | | $ | 0.90 | |
Diluted | $ | 1.57 | | | | | | | | $ | 0.89 | |
| | | | | | | | |
Sonoco Products Company
PRO FORMA CONDENSED COMBINED STATEMENT OF INCOME
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
(Dollars and shares in thousands except per share data) Year ended December 31, 2023 | Sonoco | Eviosys (as Reclassified) (see Note 4) | IFRS to U.S. GAAP Adjustments | Note | Eviosys(U.S. GAAP) | Transaction Accounting Adjustments | Note | Pro Forma Condensed Combined |
Net sales | $ | 6,781,292 | | $ | 2,602,880 | | $ | — | | | $ | 2,602,880 | | $ | (12,171) | | 8A | $ | 9,372,001 | |
Cost of sales | 5,345,638 | | 2,156,050 | | 2,215 | | 3A-3D | 2,158,265 | | (15,653) | | 8A-8C, 8E | 7,488,250 | |
Gross profit | 1,435,654 | | 446,830 | | (2,215) | | | 444,615 | | 3,482 | | | 1,883,751 | |
Selling, general and administrative expenses | 741,860 | | 217,882 | | (1,867) | | 3A-3D | 216,015 | | 105,433 | | 8C,8D, 8F-8G | 1,063,308 | |
Restructuring/Asset impairment charges | 56,933 | | 11,903 | | — | | | 11,903 | | — | | | 68,836 | |
Gain on divestiture of business and other assets
| 78,929 | | — | | — | | | — | | — | | | 78,929 | |
Operating profit | 715,790 | | 217,045 | | (348) | | | 216,697 | | (101,951) | | | 830,536 | |
Other income, net | 39,657 | | — | | — | | | — | | — | | | 39,657 | |
Non-operating pension costs | 14,312 | | 2,021 | | (253) | | 3C | 1,768 | | — | | | 16,080 | |
Interest expense | 136,686 | | 142,951 | | (1,454) | | 3A | 141,497 | | 117,788 | | 8H | 395,971 | |
Interest income | 10,383 | | 1,841 | | — | | | 1,841 | | — | | | 12,224 | |
Income before income taxes | 614,832 | | 73,914 | | 1,359 | | | 75,273 | | (219,739) | | | 470,366 | |
Provision for income taxes | 149,278 | | 36,330 | | 361 | | 3A-3E | 36,691 | | (73,882) | | 8I | 112,087 | |
Income before equity in earnings of affiliates | 465,554 | | 37,584 | | 998 | | | 38,582 | | (145,857) | | | 358,279 | |
Equity in earnings of affiliates, net of tax | 10,347 | | — | | — | | | — | | — | | | 10,347 | |
Net income | 475,901 | | 37,584 | | 998 | | | 38,582 | | (145,857) | | | 368,626 | |
Net (income)/loss attributable to noncontrolling interests | (942) | | 158 | | — | | | 158 | | — | | | (784) | |
Net income attributable to Sonoco | $ | 474,959 | | $ | 37,742 | | $ | 998 | | | $ | 38,740 | | $ | (145,857) | | | $ | 367,842 | |
Weighted average common shares outstanding: | | | | | | | | |
Basic | 98,294 | | | | | | — | | | 98,294 | |
Assuming exercise of awards | 596 | | | | | | — | | | 596 | |
Diluted | 98,890 | | | | | | — | | | 98,890 | |
Per common share | | | | | | | | |
Net income attributable to Sonoco: | | | | | | | | |
Basic | $ | 4.83 | | | | | | | | $ | 3.74 | |
Diluted | $ | 4.80 | | | | | | | | $ | 3.72 | |
| | | | | | | | |
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Note 1. Description of Acquisition
On June 22, 2024, the Company, the Seller and Eviosys, entered into a Put Option Agreement (the “Put Option Agreement”) pursuant to which the Company made a binding offer to acquire, on the terms and conditions set forth in the Purchase Agreement, all of the issued and outstanding equity interests in Eviosys for €3,615,000 (approximately $3,900,000 based on the foreign exchange rate as of June 30, 2024), on a cash-free and debt-free basis and subject to customary adjustments. Pursuant to the Put Option Agreement, on August 22, 2024, following the completion of a consultation process with the European Works Council of Eviosys and its subsidiaries, the Seller delivered an exercise notice to the Company accepting its offer and delivered to the Company a copy of the Purchase Agreement, executed by Eviosys and the Seller. Eviosys is a global supplier of metal packaging that produces food cans and ends, aerosol cans, metal closures and promotional packaging in 44 manufacturing facilities located in 17 countries across Europe, the Middle East, and Africa. The Eviosys Acquisition is expected to close in the fourth quarter of 2024 or the first quarter of 2025, subject to the expiration, termination or receipt of the waiting period or clearances, as applicable, under certain specified antitrust laws and other customary closing conditions.
Eviosys has signed a definitive agreement to exit its operations in Russia. This arrangement is subject to certain regulatory approvals, making the timing of the exit unknown. The financial statements of Eviosys include the results of Russia operations, which are considered immaterial to Sonoco’s ongoing operations following the Eviosys Acquisition.
Note 2. Description of Financing
On June 22, 2024, in conjunction with its entry into the Purchase Agreement, to secure funding of the Eviosys Acquisition, Sonoco obtained a commitment from JPMorgan Chase Bank, N.A. and Morgan Stanley Senior Funding, Inc. for a 364-day senior unsecured bridge term loan facility in an amount up to $4,000,000 (the “Bridge Loan Facility”), subject to customary conditions. On July 12, 2024, in order to finance a portion of the cash consideration for the Eviosys Acquisition, Sonoco also entered into a credit agreement with certain lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, for a $700,000 unsecured term loan facility (the “First Acquisition Term Loan Facility”) that will mature on the second anniversary of the funding date, which is expected to take place substantially concurrently with the closing of the Eviosys Acquisition. In addition, on September 13, 2024, Sonoco announced that, in order to finance a portion of the cash consideration for the Eviosys Acquisition, it had obtained commitments from certain lenders for an approximately $1,200,000 senior unsecured term loan facility (the “Second Acquisition Term Loan Facility” and, together with the First Acquisition Term Loan Facility, the “Acquisition Term Loan Facilities”). The Second Acquisition Term Loan Facility is expected to mature 364 days following the funding date, which is expected to take place substantially concurrently with the closing of the Eviosys Acquisition. The Company expects to enter into a definitive agreement with respect to the Second Acquisition Term Loan Facility on or around September 16, 2024. After the execution of a definitive agreement with respect to the Second Acquisition Term Loan Facility, the aggregate amount of the commitments under the Acquisition Term Loan Facilities will replace a corresponding amount of the commitments in respect of the Bridge Loan Facility, in accordance with its terms. The commitments in respect of the Bridge Loan Facility will be further reduced by the aggregate principal amount of any senior unsecured notes issued and sold by the Company. The Company does not expect to incur any indebtedness under the Bridge Loan Facility in connection with the closing of the Eviosys Acquisition.
The Company intends to fund the cash consideration payable by the Company in connection with the Eviosys Acquisition, including related fees and expenses, with the net proceeds from the issuance of senior unsecured notes, borrowings under the Acquisition Term Loan Facilities and cash on hand or additional borrowings under its Revolving Credit Facility. For purposes of the accompanying unaudited pro forma condensed combined financial information, as of the date of this Current Report, the Company has assumed the incurrence of an aggregate of $3,900,000 principal amount of senior indebtedness, with net proceeds to the Company of $3,879,200, at an aggregated weighted average interest rate of 6.19%, which is current as of the date the pro forma financial information is issued, and with a weighted average maturity of 3.6 years.
As part of its financing strategy the Company may enter into interest rate swaps, treasury locks, forward starting swaps, foreign currency swaps or other forms of derivative instruments to mitigate interest rate or foreign currency risk. The potential impact of such derivative instruments is not reflected in the pro forma adjustments included herein.
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Note 3. Basis of Pro Forma Presentation
The accompanying unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, “Business Combinations,” with Sonoco being the acquirer, and are based on the audited annual and unaudited interim historical consolidated financial information of Sonoco and Eviosys. The unaudited pro forma condensed combined financial information is presented for illustrative purposes only. The pro forma adjustments have been prepared as if the Eviosys Acquisition and the related financing transactions had been consummated on June 30, 2024, in the case of the unaudited pro forma condensed combined balance sheet, and as if the Eviosys Acquisition and the related financing transactions had been consummated on January 1, 2023, the beginning of the earliest period presented, in the unaudited pro forma condensed combined statements of income.
Sonoco’s historical financial statements were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and presented in U.S. dollars (“USD”). Eviosys’s historical financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board and presented in Euros. As discussed in Note 4. Eviosys Historical Financial Statement Reclassification Adjustments, the historical Eviosys financial statements were translated to USD and certain reclassifications were made to align the presentation of Eviosys’s financial statements with the presentation of Sonoco’s financial statements. The consolidated statements of income of Eviosys were translated using the average exchange rate for the six months ended June 30, 2024 of 1.08126 USD per Euro and the average exchange rate for the twelve months ended December 31, 2023 of 1.08102 USD per Euro. The consolidated balance sheet of Eviosys as of June 30, 2024 was translated using the spot rate on June 30, 2024 of 1.07146 USD per Euro.
The consolidated statement of income of Eviosys for the six months ended June 30, 2024, and the consolidated balance sheet of Eviosys as of June 30, 2024, include certain costs triggered by the Eviosys Acquisition. These one-time costs include €32 million of bonus costs and €7 million of Management Equity Plan costs, which are presented in “Selling, general and administrative expenses” in the unaudited pro forma condensed combined statement of income and “Accrued expenses and other” in the unaudited pro forma condensed combined balance sheet, respectively.
IFRS to U.S. GAAP
IFRS differs in certain respects from U.S. GAAP. The following adjustments have been made to align Eviosys’s historical accounting policies under IFRS to Sonoco’s accounting policies under U.S. GAAP for the purposes of this pro forma presentation.
(A) Leases
Under IFRS, Eviosys recognized right-of-use assets and lease liabilities for all leases as finance leases. An adjustment of $46,758 was recorded to reflect right-of-use assets relating to operating leases under U.S. GAAP and in accordance with Sonoco policies and borrowing rates, which included a $32,000 reclassification from “Other Assets” to “Right of Use Asset-Operating Leases” in the unaudited condensed combined balance sheet as of June 30, 2024. A similar adjustment of $12,272 was recorded in order to reflect the short-term operating lease liability within “Accrued expenses and other,” which included a reclassification of $11,717 from “Notes payable and current portion of long-term debt.” Additionally, an adjustment of $33,519 was recorded in order to reflect the noncurrent operating lease liability, which included a reclassification of $21,142 from “Long-term Debt” in the condensed combined balance sheet as of June 30, 2024. The adjustment resulted in an increase in the “Deferred income taxes” liability of $412 in the condensed combined balance sheet as of June 30, 2024. None of the acquired leases were classified as finance leases under U.S. GAAP.
Eviosys recorded depreciation on the right-of-use assets and interest expense on the lease liabilities. Under U.S. GAAP, a straight-line operating expense based upon the average of the gross contractual payments is recorded for operating leases. The difference in the treatment resulted in a reduction of $803 to “Interest expense,” an increase of $1,967 to “Cost of sales,” an increase of $65 to “Selling, general and administrative expenses,” and a $298 decrease in “Provision for income taxes” in the unaudited condensed combined statement of income for the six-month period ended June 30, 2024. Additionally, this IFRS to U.S. GAAP difference resulted in a reduction of $1,454 to “Interest expense,” an increase of $1,961 to “Cost of sales,” an increase of $571 to “Selling, general and administrative expenses,” and a decrease of $261 in “Provision for income taxes” in the unaudited condensed combined income statement for the year ended December 31, 2023. Expenses recorded to the “Selling, general and
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
administrative expenses” line item relate to leases for administrative related activities, whereas lease expenses recorded to the “Cost of sales” line item are related to plant activities.
(B) Turkey Hyperinflation
Eviosys’s reclassified unaudited condensed combined statement of income was converted to USD by translating at month-to-date exchange rates and adjusting for the hyperinflationary impact of the Turkish lira from Eviosys's operations in Turkey. The adjustment removes the hyperinflationary impact based on a hyperinflationary index in accordance with IFRS and treats USD as the functional currency in accordance with U.S. GAAP requirements for hyperinflation.
For the six-month period ended June 30, 2024, the adjustment resulted in reductions to “Cost of sales” and “Selling, general and administrative expenses” of $919 and $2,144, respectively, and an increase in “Provision for income taxes” of $765.
For the year ended December 31, 2023, the adjustment resulted in reductions to “Cost of sales” and “Selling, general and administrative expenses” of $1,261 and $2,943, respectively, and an increase in “Provision for income taxes” of $1,050.
(C) Pension and Postretirement Plans
Changes associated with assumed discount rates on plan obligations and expected returns on plan assets under U.S. GAAP as compared to IFRS resulted in a $23 increase to “Other Assets,” a $2,655 increase to “Accrued expenses and other,” an $826 increase to “Pension and Other Postretirement Benefits,” and the elimination of the pre-acquisition “Accumulated other comprehensive loss” balance of $16,133 in the unaudited pro forma condensed combined balance sheet as of June 30, 2024. The adjustment resulted in a decrease in the “Deferred income taxes” liability of $803 in the condensed combined balance sheet as of June 30, 2024.
Additionally, these changes in assumptions resulted in net decreases of $9 and $253 in “Non-operating pension costs” in the unaudited pro forma condensed combined statements of income for the six-month period ended June 30, 2024 and the year ended December 31, 2023, respectively, and aggregate increases of $227 and $1,164 to “Cost of sales” and “Selling, general and administrative expenses” combined in the unaudited pro forma condensed combined statements of income for the six-month period ended June 30, 2024 and the year ended December 31, 2023, respectively. The adjustments resulted in decreases of $53 and $221 in “Provision for income taxes” in the unaudited pro forma condensed combined statements of income for the six-month period ended June 30, 2024 and the year ended December 31, 2023, respectively.
(D) Long Service Employee Benefit Awards
Changes associated with assumed discount rates on award obligations and gain/(loss) recognition assumptions under U.S. GAAP as compared to IFRS resulted in a $634 increase to “Accrued expenses and other” and a $2,388 decrease to “Other Liabilities” in the unaudited pro forma condensed combined balance sheet as of June 30, 2024. The adjustment resulted in an increase in the “Deferred income taxes” liability of $407 in the condensed combined balance sheet as of June 30, 2024. Additionally, changes associated with discount rate assumptions resulted in an aggregate increase of $385 and $856 to “Cost of sales” and “Selling, general and administrative expenses” combined in the unaudited pro forma condensed combined statements of income for the six-month period ended June 30, 2024 and the year ended December 31, 2023, respectively. The adjustments resulted in decreases of $93 and $207 in “Provision for income taxes” in the unaudited pro forma condensed combined statements of income for the six-month period ended June 30, 2024 and the year ended December 31, 2023, respectively.
(E) Debt Renegotiation
Eviosys recognized a gain under IFRS related to a debt modification catch-up adjustment on a repriced term loan facility as of June 30, 2024. U.S. GAAP does not allow for a debt repricing as part of a debt modification to be recognized in the income statement. Therefore, an adjustment was made to remove the $12,778 offset to “Interest expense” in the unaudited pro forma condensed combined statement of income for the six-month period ended June 30, 2024 with a corresponding increase to “Long-term Debt.” The adjustment resulted in a decrease of $3,275 in “Provision for income taxes” in the unaudited pro forma condensed combined statement of income for the six-month period ended June 30, 2024.
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Further detailed review of Eviosys’s historical accounting policies under IFRS may identify additional differences between the accounting policies of the two companies that, when conformed, could have a material impact in the financial statements of the combined company. However, at this time, Sonoco is not aware of any additional accounting policy differences between IFRS and U.S. GAAP that would have a material impact in the unaudited condensed combined pro forma information that are not reflected in the pro forma financial information.
Note 4. Eviosys Historical Financial Statement Reclassification Adjustments
Certain reclassifications were made to align the presentation of the Eviosys historical financial statements with the presentation of Sonoco’s historical financial statements. The tables below summarize such reclassifications made to the Eviosys historical balance sheet and statements of income based on information available to date:
Eviosys’s Unaudited Reclassified Condensed Combined Balance Sheet as of June 30, 2024:
| | | | | | | | | | | | | | | | | | | | |
Presentation in Eviosys’s Historical Financial Statements | Presentation in Unaudited Pro Forma Condensed Combined Balance Sheet | Eviosys before Reclassifications (EUR) | Reclassified Amounts (EUR) | | Eviosys as Reclassified (EUR) | Eviosys as Reclassified (USD) |
Cash & cash equivalents | Cash and cash equivalents | € | 196,382 | | € | — | | | € | 196,382 | | $ | 210,415 | |
Trade receivables | Trade accounts receivable, net | 200,098 | | — | | | 200,098 | | 214,397 | |
Contract receivables | Other receivables | 60,664 | | — | | | 60,664 | | 64,998 | |
Other receivables | Other receivables | 41,557 | | — | | | 41,557 | | 44,527 | |
Current tax receivables | Other receivables | 10,047 | | — | | | 10,047 | | 10,765 | |
Inventory | Finished and in process | 521,433 | | (233,067) | | (a) | 288,366 | | 308,973 | |
| Materials and supplies | | 233,067 | | (a) | 233,067 | | 249,721 | |
Current financial assets | Prepaid expenses | 13,790 | | (1,103) | | (b) | 12,687 | | 13,594 | |
| Other Assets | | 1,103 | | (b) | 1,103 | | 1,181 | |
Other current assets | Prepaid expenses | 24,512 | | — | | | 24,512 | | 26,264 | |
Property, plant and equipment | Property, Plant and Equipment, Net | 824,009 | | — | | | 824,009 | | 882,891 | |
Right-of-use assets | Other Assets | 29,866 | | — | | | 29,866 | | 32,000 | |
Intangible assets | Other Intangible Assets, Net | 1,340,736 | | (826,431) | | (c) | 514,305 | | 551,056 | |
| Goodwill | | 826,431 | | (c) | 826,431 | | 885,486 | |
Deferred tax asset | Deferred Income Taxes | 22,143 | | — | | | 22,143 | | 23,725 | |
Other non-current assets | Other Assets | 4,326 | | — | | | 4,326 | | 4,635 | |
Short-term debt | Notes payable and current portion of long-term debt | 1,534 | | — | | | 1,534 | | 1,644 | |
Trade payable | Payable to suppliers | 527,448 | | — | | | 527,448 | | 565,138 | |
Current lease liabilities | Notes payable and current portion of long-term debt | 10,936 | | — | | | 10,936 | | 11,717 | |
Income taxes payable | Accrued taxes | 14,594 | | — | | | 14,594 | | 15,637 | |
Current financial liabilities | Accrued expenses and other | 3,957 | | — | | | 3,957 | | 4,240 | |
Other current liabilities | Accrued expenses and other | 253,196 | | — | | | 253,196 | | 271,289 | |
Long-term debt | Long-term Debt | 1,907,553 | | — | | | 1,907,553 | | 2,043,862 | |
Non-current lease liabilities | Long-term Debt | 19,732 | | — | | | 19,732 | | 21,142 | |
Employee benefits | Pension and Other Postretirement Benefits | 59,955 | | (9,735) | | (d) | 50,220 | | 53,809 | |
| Other Liabilities | | 9,735 | | (d) | 9,735 | | 10,431 | |
Deferred tax liability | Deferred Income Taxes | 201,479 | | — | | | 201,479 | | 215,876 | |
Other non-current provisions | Other Liabilities | 3,167 | | — | | | 3,167 | | 3,393 | |
Non-current financial liabilities | Other Liabilities | 2,124 | | — | | | 2,124 | | 2,276 | |
Other non-current liabilities | Other Liabilities | 2,987 | | — | | | 2,987 | | 3,200 | |
Non-controlling interest | Noncontrolling Interests | 19,030 | | — | | | 19,030 | | 20,390 | |
Reserves | Retained earnings | 261,871 | | (296,659) | | (e) | (34,788) | | (37,274) | |
| Capital in excess of stated value | | 295,140 | | (e) | 295,140 | | 316,230 | |
| Accumulated other comprehensive loss | | 1,519 | | (e) | 1,519 | | 1,628 | |
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
(a) Inventories that were presented on a combined basis in Eviosys’s historical financial statements have been separately presented as “Finished and in process” and “Materials and supplies” in order to conform with Sonoco’s presentation.
(b) “Current financial assets” in the Eviosys historical balance sheet includes €1,103 of items that were reclassified to “Other Assets” in order to conform with Sonoco’s presentation.
(c) “Intangible assets” that were presented on a combined basis in Eviosys’s historical financial statements have been separately presented as “Goodwill” and “Other Intangible Assets, Net” in order to conform with Sonoco’s presentation.
(d) The non-current liability “Employee benefits” in the Eviosys historical balance sheet includes long service award obligations of €9,735 that are presented as “Other Liabilities” in order to conform with Sonoco’s presentation.
(e) “Reserves” in the Eviosys historical balance sheet have been broken out and separately presented in “Capital in excess of stated value,” “Accumulated other comprehensive loss,” and “Retained earnings” in order to conform with Sonoco’s presentation.
Eviosys’s Unaudited Reclassified Condensed Combined Statement of Income for the six months ended June 30, 2024:
| | | | | | | | | | | | | | | | | | | | |
Presentation in Eviosys’s Historical Financial Statements | Presentation in Unaudited Pro Forma Condensed Combined Statement of Income | Eviosys before Reclassifications (EUR) | Reclassified Amounts (EUR) | | Eviosys as Reclassified (EUR) | Eviosys as Reclassified (USD) |
Revenue | Net sales | € | 1,054,254 | | € | — | | | € | 1,054,254 | | $ | 1,139,921 | |
Cost of product sold | Cost of sales | 879,345 | | — | | | 879,345 | | 950,798 | |
Selling, general and administration expenses | Selling, general and administrative expenses | 93,105 | | — | | | 93,105 | | 100,667 | |
Other expenses, net | Restructuring/Asset impairment charges | 6,533 | | (513) | | (a) | 6,020 | | 6,509 | |
| Selling, general and administrative expenses | | 513 | | (a) | 513 | | 555 | |
Amortization of Intangible assets | Selling, general and administrative expenses | 26,528 | | — | | | 26,528 | | 28,684 | |
Finance expense | Interest expense | 70,737 | | (11,851) | | (b)(c)(d) | 58,886 | | 63,671 | |
| Interest income | | (1,475) | | (b) | (1,475) | | (1,595) | |
| Selling, general and administrative expenses | | 12,556 | | (c) | 12,556 | | 13,576 | |
| Non-operating pension costs | | 770 | | (d) | 770 | | 833 | |
Foreign exchange loss | Cost of sales | 1,137 | | — | | | 1,137 | | 1,229 | |
IAS 29 Net monetary loss | Selling, general and administrative expenses | 3,183 | | (955) | | (e) | 2,228 | | 2,409 | |
| Cost of sales | | 955 | | (e) | 955 | | 1,034 | |
Income tax | Provision for income taxes | 4,335 | | — | | | 4,335 | | 4,687 | |
Profit attributable to non-controlling interest | Net (income)/loss attributable to noncontrolling interests | 417 | | — | | | 417 | | 451 | |
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Eviosys’s Unaudited Reclassified Condensed Combined Statement of Income for the year ended December 31, 2023:
| | | | | | | | | | | | | | | | | | | | |
Presentation in Eviosys’s Historical Financial Statements | Presentation in Unaudited Pro Forma Condensed Combined Statement of Income | Eviosys before Reclassifications (EUR) | Reclassified Amounts (EUR) | | Eviosys as Reclassified (EUR) | Eviosys as Reclassified (USD) |
Revenue | Net sales | € | 2,407,810 | | € | — | | | € | 2,407,810 | | $ | 2,602,880 | |
Cost of product sold | Cost of sales | 1,991,107 | | — | | | 1,991,107 | | 2,152,418 | |
Selling, general and administration expenses | Selling, general and administrative expenses | 112,091 | | — | | | 112,091 | | 121,173 | |
Other expense, net | Restructuring/Asset impairment charges | 13,827 | | (2,816) | | (a) | 11,011 | | 11,903 | |
| Selling, general and administrative expenses | | 2,816 | | (a) | 2,816 | | 3,044 | |
Amortization of Intangible assets | Selling, general and administrative expenses | 52,736 | | — | | | 52,736 | | 57,008 | |
Finance expense | Interest expense | 160,657 | | (28,419) | | (b)(c)(d) | 132,238 | | 142,951 | |
| Interest income | | (1,703) | | (b) | (1,703) | | (1,841) | |
| Selling, general and administrative expenses | | 28,252 | | (c) | 28,252 | | 30,541 | |
| Non-operating pension costs | | 1,870 | | (d) | 1,870 | | 2,021 | |
Foreign exchange loss | Cost of sales | 935 | | — | | | 935 | | 1,011 | |
IAS 29 Net monetary loss | Selling, general and administrative expenses | 8,083 | | (2,425) | | (e) | 5,658 | | 6,116 | |
| Cost of sales | | 2,425 | | (e) | 2,425 | | 2,621 | |
Income tax | Provision for income taxes | 33,607 | | — | | | 33,607 | | 36,330 | |
Profit attributable to non-controlling interest | Net (income)/loss attributable to noncontrolling interests | (146) | | — | | | (146) | | (158) | |
(a) “Other expense, net” in the historical financial statements of Eviosys consists primarily of restructuring charges as well as bad debt expense and other miscellaneous expenses. In order to conform with Sonoco’s presentation, the restructuring charges are reflected under “Restructuring/Asset impairment charges” and €513 and €2,816 of bad debt expense and other miscellaneous expenses combined were reclassified to “Selling, general and administrative expenses” for the six-month period ended June 30, 2024 and for the year ended December 31, 2023, respectively.
(b) The historical financial statements of Eviosys include interest income within the line item “Finance expense.” Therefore, in order to conform with Sonoco’s presentation, interest income of €1,475 and €1,703 for the six-month period ended June 30, 2024 and for the year ended December 31, 2023, respectively, were reclassified to “Interest income.”
(c) The historical financial statements of Eviosys include factoring and securitization expense within the line item “Finance expense.” Therefore, in order to conform with Sonoco’s presentation, factoring and securitization expense of €12,556 and €28,252 for the six-month period ended June 30, 2024 and for the year ended December 31, 2023, respectively, were reclassified to “Selling, general and administrative expenses.”
(d) The historical financial statements of Eviosys include non-operating pension costs within the line item “Finance expense.” Therefore, in order to conform with Sonoco’s presentation, non-operating pension costs of €770 and €1,870 for the six-month period ended June 30, 2024 and for the year ended December 31, 2023, respectively, were reclassified to “Non-operating pension costs.”
(e) The reclassified income statement of Eviosys was converted to USD by translating at month-to-date exchange rates and adjusting for the hyperinflationary impact of the Turkish lira. The hyperinflationary impact was reflected in the line item “IAS 29 Net monetary loss” in the historical financial statements of Eviosys. In order to conform with Sonoco’s presentation, the hyperinflationary impact was bifurcated between “Selling, general and administrative expenses” and “Cost of sales” with €955 and €2,425 reclassified to “Cost of sales” for the six-month period ended June 30, 2024 and for the year ended December 31, 2023, respectively.
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Note 5. Consideration Transferred
The following table summarizes the assumed consideration transferred to consummate the Eviosys Acquisition:
| | | | | |
Cash Consideration to Eviosys Sellers | $ | 1,624,067 | |
Cash Repayment of Eviosys Debt, Other Expenses and Estimated Working Capital Adjustment | 2,249,132 | |
| |
Total Purchase Consideration | $ | 3,873,199 | |
| |
Less: Estimated Cash Acquired | 210,415 | |
Total Purchase Consideration, net of Cash Acquired | $ | 3,662,784 | |
Note 6. Fair Value Estimate of Assets Acquired and Liabilities Assumed
The table below represents an preliminary allocation of the estimated purchase consideration to Eviosys’s tangible and intangible assets acquired and liabilities assumed based on management’s preliminary estimate of their respective fair values as if the Eviosys Acquisition had been consummated on June 30, 2024. The Company has not completed its evaluation of the fair value of assets acquired and liabilities assumed and, accordingly, the adjustments to record the fair value of assets acquired and liabilities assumed at the acquisition date reflect the best estimates of the Company based on the information currently available and are subject to change following the completion of the Eviosys Acquisition and once additional analyses and ongoing valuation work are completed. The changes may be material.
| | | | | |
Total Purchase Consideration | $ | 3,873,199 | |
Cash and cash equivalents | $ | 210,415 | |
Trade accounts receivable | 214,354 | |
Other receivables | 120,290 | |
Inventories | |
Finished and in process | 326,275 | |
Materials and supplies | 177,547 | |
Prepaid expenses | 29,770 | |
Property, plant and equipment | 1,073,387 | |
Right of use asset - operating leases | 46,758 | |
Other intangible assets | 2,018,091 | |
Deferred taxes | 10,905 | |
Other assets | 5,838 | |
Total Assets Acquired | $ | 4,233,630 | |
| |
Payable to suppliers | $ | 565,095 | |
Accrued expenses and other | 226,851 | |
| |
Accrued taxes | 15,637 | |
| |
| |
Noncurrent operating lease liabilities | 33,519 | |
Pension and other postretirement benefits | 54,635 | |
Deferred income taxes | 604,429 | |
Other liabilities | 14,638 | |
Total Liabilities Assumed | $ | 1,514,804 | |
Net Assets Acquired, excluding Goodwill | $ | 2,718,826 | |
Goodwill | 1,154,373 | |
Total Estimated Fair Value of Net Assets Acquired | $ | 3,873,199 | |
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Note 7. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet
Explanations of the adjustments to the unaudited pro forma condensed combined balance sheet as of June 30, 2024 are as follows:
(A) Cash and cash equivalents
An adjustment to incorporate the estimated effects of the following inflows and outflows as a result of the Eviosys Acquisition and the related financing transactions. The following table presents the components of the transaction adjustments relating to cash and cash equivalents:
| | | | | |
Net proceeds received from financing | $ | 3,879,200 | |
Cash consideration to Eviosys sellers | (1,624,067) | |
Cash repayment of Eviosys debt, including accrued interest | (2,197,903) | |
Payment of seller fees and other expenses | (51,229) | |
Cash used for operations | (6,001) | |
Total | $ | — | |
(B) Trade accounts receivable, net of allowances
Trade receivables, net of allowances as of June 30, 2024, were reduced by $2,832 to eliminate trade receivables related to transactions between Sonoco and Eviosys.
(C) Inventories
“Finished and in process” inventories were increased by $17,302 to reflect a purchase accounting fair value adjustment. The adjustment was determined based on the estimated selling prices of the inventory, less the estimated remaining manufacturing and selling costs, and normal profit margins on those manufacturing and selling efforts.
The pro forma condensed combined income statement for the year ended December 31, 2023 was adjusted to increase “Cost of sales” by $17,302 to reflect the fair value adjustment to acquired inventory as the acquired inventory is expected to be sold within one year of the acquisition date. See Note 8B for additional information.
Under Sonoco’s inventory capitalization policy, all spare parts with an extended unit value of less than five hundred dollars are expensed whereas Eviosys capitalized all spare parts regardless of the unit value. Also under Sonoco’s inventory capitalization policy certain packaging materials are expensed whereas Eviosys records these materials in inventory. Adjustments for these policy differences totaling $72,174 were included in “Materials and supplies” in Eviosys’s unaudited reclassified condensed combined balance sheet as of June 30, 2024. Accordingly, an adjustment was made to reduce both “Materials and supplies” and “Retained earnings” by $72,174, in order to align Eviosys’s presentation with Sonoco’s policy.
(D) Prepaid expenses
Prepaid expenses were reduced by $10,088 to eliminate Eviosys’s fair value position of interest rate swaps as of June 30, 2024. This adjustment was the result of the anticipated repayment of Eviosys’s debt and termination of the related interest rate swaps.
(E) Property, Plant and Equipment, net
Represents the preliminary fair value and resulting pro forma accounting adjustment to “Property, Plant and Equipment, Net.” The preliminary amounts assigned to these assets and estimated weighted average useful lives are as follows:
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
| | | | | | | | |
| Fair Value | Weighted Average Useful Lives (Years) |
Land | $ | 182,791 | | N/A |
Land improvements | 3,322 | | 6.0 |
Buildings and improvements | 379,939 | | 16.0 |
Machinery and equipment | 397,618 | | 8.8 |
Construction in progress | 109,717 | | N/A |
Total | 1,073,387 | | |
Less: Historical Eviosys value (as reclassified) | (882,891) | | |
Pro forma adjustment | $ | 190,496 | | |
Sonoco expenses all start-up costs related to placing assets into service whereas Eviosys capitalizes certain start-up costs. Start-up costs of $1,179 were included in “Property, plant and equipment, net” in Eviosys's Unaudited Reclassified Condensed Combined Balance Sheet as of June 30, 2024. Accordingly, a pro forma adjustment was made to reduce both “Property, Plant and Equipment, Net” and “Retained earnings” by $1,179 in order to align Eviosys’s presentation with Sonoco’s policy.
(F) Goodwill
Represents the purchase accounting and related deferred income tax adjustments to goodwill, which is the excess of the preliminary consideration over the preliminary fair value of the assets acquired and liabilities assumed. Goodwill will be tested for impairment annually and whenever events or circumstances have occurred that may indicate a possible impairment. None of the goodwill associated with the Eviosys Acquisition is expected to be deductible for income tax purposes.
(G) Other Intangible Assets, Net
Represents the preliminary fair value and resulting purchase accounting adjustment to intangible assets (other than goodwill). The preliminary amounts assigned to intangible assets and estimated weighted average useful lives are as follows:
| | | | | | | | |
| Fair Value | Weighted Average Useful Lives (Years) |
Customer lists | $ | 1,741,119 | | 20.0 |
Trade names | 143,040 | | 6.2 |
Process know-how | 128,575 | | 11.5 |
Patents | 5,357 | | 4.7 |
Total | 2,018,091 | | |
Less: Historical Eviosys value (as reclassified) | (551,056) | | |
Pro forma adjustment | $ | 1,467,035 | | |
(H) Long-term Deferred Income Tax Asset
Represents the estimated net long-term deferred income tax asset adjustments related to the preliminary fair value of assets acquired and liabilities assumed. Differences between these preliminary estimates and the final acquisition accounting are likely to occur and may be materially different from these estimates.
(I) Payable to suppliers
“Payable to suppliers” as of June 30, 2024 was reduced by $2,832 to eliminate trade payables related to transactions between Sonoco and Eviosys.
(J) Accrued expenses and other
The pro forma adjustments to “Accrued expenses and other” include the following:
•an estimated $38,514 of additional acquisition-related transaction costs expected to be incurred by Sonoco subsequent to June 30, 2024;
•a $5,000 adjustment for estimated retention bonuses for certain Eviosys employees subsequent to the Eviosys Acquisition;
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
•a $(42,834) adjustment to decrease accrued bonuses and liabilities under the Eviosys management equity plan triggered by the anticipated change of control resulting from the probable acquisition of Eviosys by Sonoco, which Eviosys included on its balance sheet as of June 30, 2024; and
•a $(21,406) adjustment for the anticipated repayment of Eviosys’s debt and related accrued interest payable.
(K) Notes payable and current portion of long-term debt
Represents adjustments to “Notes payable and current portion of long-term debt” due to the following inflows and outflows resulting from the Eviosys Acquisition:
| | | | | |
Short-term portion of net proceeds received from financing | $ | 1,197,000 | |
Elimination of historical Eviosys current portion of long-term debt | (1,644) | |
Pro forma adjustment | $ | 1,195,356 | |
(L) Long-term Debt
Represents adjustments to “Long-term Debt” due to the following inflows and outflows resulting from the Eviosys Acquisition:
| | | | | |
Long-term portion of net proceeds received from financing | $ | 2,682,200 | |
Elimination of remaining historical Eviosys long-term debt | (2,056,525) | |
Pro forma adjustment | $ | 625,675 | |
(M) Long-term Deferred Income Tax Liability
Represents the estimated net long-term deferred income tax liability adjustments related to the preliminary fair value of assets acquired and liabilities assumed. Differences between these preliminary estimates and the final acquisition accounting are likely to occur and may be materially different from these estimates.
(N) Other Liabilities
“Other Liabilities” were reduced by $2,275 to eliminate Eviosys’s fair value position of interest rate swaps as of June 30, 2024.
(O) Capital in excess of stated value
The pro forma adjustment to “Capital in excess of stated value” reflects the elimination of Eviosys’s historical capital in excess of stated value from the unaudited pro forma condensed combined balance sheet as of June 30, 2024.
(P) Accumulated other comprehensive loss
“Accumulated other comprehensive loss” was increased by $7,813 to eliminate Eviosys’s fair value position of interest rate swaps as of June 30, 2024. An offsetting $22,318 pro forma reduction was also included for the elimination of the portion of Eviosys’s historical accumulated other comprehensive loss associated with currency translation adjustments from the unaudited pro forma condensed combined balance sheet as of June 30, 2024.
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
(Q) Retained earnings
The following pro forma adjustments impacted retained earnings:
| | | | | |
| Pro Forma Adjustment |
Additional transaction costs incurred by Sonoco (see Note 8G) | $ | (38,514) | |
Accrual of retention bonus payable to Eviosys employees (see Note 8F) | (5,000) | |
Elimination of remaining historical Eviosys retained earnings | 33,797 | |
Purchase accounting adjustments impacting retained earnings | (6,100) | |
Pro forma adjustment | $ | (15,817) | |
(R) Noncontrolling Interests
Eviosys’s historical financial statements reflect noncontrolling interests related to joint ventures in Morocco and the Ivory Coast in which Eviosys is a majority shareholder. For purposes of the unaudited pro forma condensed combined financial information, it has been assumed that the remaining ownership interest in these joint ventures is acquired as part of the Eviosys Acquisition. Therefore, an adjustment has been made to eliminate the $20,390 balance in “Noncontrolling interests” in the unaudited pro forma condensed combined balance sheet as of June 30, 2024.
Note 8. Adjustments to Unaudited Pro Forma Condensed Combined Statement of Income
Explanations of the adjustments to the unaudited pro forma condensed combined statement of income are as follows:
(A) Intercompany transactions – net sales and cost of sales
The adjustment to eliminate intercompany revenue and expense related to transactions between Sonoco and Eviosys included reductions of “Net sales” and “Cost of sales” of $7,917 and $7,475, respectively, for the six-month period ended June 30, 2024 and reductions of “Net sales” and “Cost of sales” of $12,171 and $11,843, respectively, for the year ended December 31, 2023.
(B) Inventory – cost of sales
The historical inventory for Eviosys as of June 30, 2024 has been adjusted to increase inventories by $17,302 to reflect the estimated fair value adjustment of finished goods and work in process inventory. The fair value was determined based on the estimated selling prices of the inventory, less the estimated remaining manufacturing and selling costs, and a normal profit margin on those manufacturing and selling efforts. The unaudited pro forma condensed combined statement of income for the year ended December 31, 2023 has been adjusted to increase “Cost of sales” by the same amount, as the inventory is expected to be sold within one year of the acquisition date.
Sonoco expenses all spare parts with a unit value of less than five hundred dollars whereas Eviosys capitalized all spare parts regardless of the unit value. Accordingly, “Cost of sales” was increased by $873 for the six-month period ended June 30, 2024 and $1,150 for the year ended December 31, 2023 in order to align Eviosys’s presentation with Sonoco’s spare parts capitalization policy.
See additional pro forma adjustments related to cost of sales in Notes 8A, 8C, and 8E.
(C) Depreciation expense – cost of sales and selling, general and administrative expenses
A depreciation expense adjustment was determined related to the acquisition date fair value adjustments made to acquired tangible assets. The following table is a summary of information related to certain tangible assets to be acquired, including information used to calculate the pro forma change in depreciation expense that is adjusted to “Cost of sales” and “Selling, general and administrative expenses.”
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
| | | | | | | | | | | | | | | | | |
| Fair Value | Weighted Average Useful Lives ( Years) | Depreciation Expense For the Six Months Ended June 30, 2024 | | Depreciation Expense For the Year Ended December 31, 2023 |
Land Improvements | $ | 3,322 | | 6.0 | $ | 275 | | | $ | 554 | |
Buildings and Improvements | 379,939 | | 16.0 | 11,808 | | | 23,746 | |
Machinery & Equipment | 397,618 | | 8.8 | 22,363 | | | 44,971 | |
Total | | | $ | 34,446 | | | $ | 69,271 | |
Less: Historical Eviosys depreciation expense | | | (41,951) | | | (94,373) | |
Pro forma adjustment | | | $ | (7,505) | | | $ | (25,102) | |
| | | | | |
Pro forma adjustment - cost of sales | | | $ | (6,811) | | | $ | (22,262) | |
Pro forma adjustment - selling, general and administrative expenses | | | (694) | | | (2,840) | |
Pro forma adjustment | | | $ | (7,505) | | | $ | (25,102) | |
| | | | | |
See additional pro forma adjustments related to “Cost of sales” in Notes 8A-8B and 8E and to “Selling, general and administrative expenses” in Notes 8D and 8F-8G.
(D) Amortization expense – selling, general and administrative expenses
An amortization expense adjustment was determined related to the acquisition date fair value adjustments made to acquired intangible assets. The following table is a summary of information related to certain intangible assets acquired, including information used to calculate the pro forma change in amortization expense that is adjusted to “Selling, general and administrative expenses:”
| | | | | | | | | | | | | | |
| Fair Value | Weighted Average Useful Lives (Years) | Amortization Expense for the Six Months Ended June 30, 2024 | Amortization Expense for the Year Ended December 31, 2023 |
Customer lists | $ | 1,741,119 | | 20 | $ | 43,290 | | $ | 87,056 | |
Trade names | 143,040 | | 6.2 | 13,125 | | 26,394 | |
Patents | 5,357 | | 4.7 | 727 | | 1,461 | |
Process know-how | 128,575 | | 11.5 | 5,559 | | 11,180 | |
Total | $ | 2,018,091 | | | 62,701 | | 126,091 | |
Less: Historical Eviosys amortization expense | | | (28,683) | | (57,007) | |
Pro forma adjustment | | | $ | 34,018 | | $ | 69,084 | |
See additional pro forma adjustments related to “Selling, general and administrative expenses” in Notes 8C and 8F-8G.
(E) Start-up costs – cost of sales
Sonoco expenses all start-up costs related to placing assets into service whereas Eviosys capitalizes certain start-up costs. In order to align Eviosys’s presentation with Sonoco’s policy, an adjustment to increase “Cost of sales” of $1,179 was made for the six-month period ended June 30, 2024. No adjustment was required for the year ended December 31, 2023.
(F) Retention bonuses – selling, general and administrative expenses
Certain Eviosys employees are expected to be eligible to receive retention bonuses subsequent to the Eviosys Acquisition. Accordingly, a pro forma adjustment in the amount of $5,000 has been included as an increase to “Selling, general and administrative expenses” during the year ended December 31, 2023 to reflect such retention bonuses as having been earned during the pro forma period as if the Eviosys Acquisition had occurred on January 1, 2023.
(G) Transaction costs – selling, general and administrative expenses
The pro forma adjustments to “Selling, general and administrative expenses” for the year ended December 31, 2023 include $38,514 of estimated additional Eviosys Acquisition-related transaction costs expected to be
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
incurred subsequent to June 30, 2024. These costs will not affect the Company’s income statement beyond 12 months of the acquisition date.
The Seller is an affiliate of KPS Capital Partners, LLC (“KPS”). KPS or its affiliates provided certain corporate advisory services for which Eviosys was charged fees of $2,720 during the six-month period ended June 30, 2024 and $4,324 during the year ended December 31, 2023.
(H) Interest expense
The pro forma adjustments to “Interest expense” represent the estimated difference in interest expense associated with the expected net additional borrowings used to fund the Eviosys Acquisition as compared to the interest expense reported on Eviosys’s historical income statement for the six-month period ended June 30, 2024 and the year ended December 31, 2023.
The following table presents the pro forma “Interest expense” adjustments: | | | | | | | | | | | |
| For the Six Months Ended June 30, 2024 | | For the Year Ended December 31, 2023 |
Interest expense on net additional borrowings used to fund the Eviosys Acquisition | $ | 78,257 | | | $ | 240,286 | |
Amortization of bridge loan financing fees | — | | | 19,000 | |
Eliminate Eviosys historical interest expense | (62,868) | | | (141,498) | |
Pro forma adjustment | $ | 15,389 | | | $ | 117,788 | |
For purposes of preparing the unaudited pro forma condensed combined financial information, the weighted average interest rate assumed for the aggregate additional borrowings used to fund the Eviosys Acquisition was 6.19%. A change in the assumed variable interest rates of the Acquisition Term Loan Facilities of 0.125% would change pro forma interest expense by approximately $2,369 per year.
In June 2024, Sonoco paid $19,000 in financing fees related to the Bridge Loan Facility. These fees were recorded as “Prepaid expenses” on Sonoco’s historical unaudited condensed consolidated balance sheet as of June 30, 2024. For purposes of the unaudited pro forma condensed combined financial information, the full amount of these fees is reflected as “Interest expense” for the year ended December 31, 2023.
(I) Income tax expense
An adjustment to incorporate the estimated tax effect of the taxable pro forma adjustments related to the Eviosys Acquisition was calculated using tax rates in effect for the countries in which Eviosys operates. This resulted in a combined blended statutory income tax rate of 26.0% and 23.8% for the six-month period ended June 30, 2024 and the year ended December 31, 2023, respectively. The effective tax rate of the combined company could be significantly different as the legal entity structure and activities of the combined company are integrated.
Sonoco Products Company
Notes to the Unaudited Pro Forma Condensed Combined Financial Information
(currency amounts and shares in thousands, except per share data)
Note 9. Pro Forma Net Income per Share
| | | | | | | | |
Consolidated | For the Six Months Ended June 30, 2024 | For the Year Ended December 31, 2023 |
Pro Forma Net Income Attributable to Sonoco | $ | 88,459 | | $ | 367,842 | |
| | |
Weighted Average Shares: | | |
Basic | 98,583 | | 98,294 | |
Assuming exercise of awards | 616 | | 596 | |
Diluted | 99,199 | | 98,890 | |
| | |
Pro Forma Net Income Per Share - Basic | $ | 0.90 | | $ | 3.74 | |
Pro Forma Net Income Per Share - Diluted | $ | 0.89 | | $ | 3.72 | |
Pro Forma Net Income Per Share - Basic has been calculated based on the estimated weighted average number of shares of Sonoco’s common stock that would have been outstanding during the six-month period ended June 30, 2024 and the year ended December 31, 2023.
Pro Forma Net Income Per Share - Diluted is computed by dividing Pro Forma Net Income Attributable to Sonoco by the weighted average shares outstanding, assuming all dilutive potential common shares were issued, unless doing so is anti-dilutive. For purposes of the pro forma condensed consolidated financial information, no new shares have been assumed to be issued in connection with the probable Eviosys Acquisition.
UNAUDITED SUPPLEMENTAL NON-GAAP PRO FORMA FINANCIAL INFORMATION
Background
As previously announced, on June 22, 2024, Sonoco Products Company (“Sonoco” or the “Company”), Titan Holdings Coöperatief U.A., a cooperative with excluded liability (coöperatie met uitgesloten aansprakelijkheid), incorporated under the laws of the Netherlands (the “Seller”), and Titan Holdings I B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (“Eviosys”), entered into a Put Option Agreement (the “Put Option Agreement”) pursuant to which the Company made a binding offer to acquire, on the terms and conditions set forth in the Equity Purchase Agreement, dated as of June 22, 2024, by and among the Company, the Seller and Eviosys (the “Purchase Agreement”), all of the issued and outstanding equity interests in Eviosys for €3,615,000 (approximately $3,900,000 based on the exchange rate as of June 30, 2024), on a cash-free and debt-free basis and subject to customary adjustments (the “Eviosys Acquisition”). Pursuant to the Put Option Agreement, on August 22, 2024, following the completion of a consultation process with the European Works Council of Eviosys and its subsidiaries, the Seller delivered an exercise notice to the Company accepting its offer and delivered to the Company a copy of the Purchase Agreement, executed by Eviosys and the Seller.
Unaudited Supplemental Non-GAAP Pro Forma Financial Information
The Company is furnishing this Exhibit 99.4 to provide certain unaudited supplemental non-GAAP pro forma financial information with respect to the proposed Eviosys Acquisition. The Company has provided unaudited pro forma condensed combined financial information of Sonoco and Eviosys and notes thereto prepared in accordance with Article 11 of Regulation S-X in Exhibit 99.3 to the Company’s Current Report on Form 8-K filed on September 13, 2024, to which this Exhibit 99.4 is attached (the “Current Report”).
This Exhibit 99.4 includes certain financial performance measures that are not in conformity with U.S. generally accepted accounting principles (“GAAP”), including Sonoco Adjusted EBITDA, Sonoco Adjusted EBITDA Margin, pro forma Adjusted EBITDA, and pro forma Adjusted EBITDA Margin. Sonoco Adjusted EBITDA and Sonoco Adjusted EBITDA Margin are derived from Sonoco’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2023 and its unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Pro forma Adjusted EBITDA and Pro forma Adjusted EBITDA Margin are derived from the unaudited pro forma condensed combined financial information of Sonoco and Eviosys and notes thereto filed as Exhibit 99.3 to this Current Report on Form 8-K. Refer to Exhibit 99.3 to this Current Report on Form 8-K for additional information regarding such pro forma condensed combined financial information.
Sonoco Adjusted EBITDA is defined as net income attributable to Sonoco, excluding the following: interest expense; interest income; provision for income taxes; depreciation, depletion and amortization expense; non-operating pension costs; net income/loss attributable to noncontrolling interests; restructuring/asset impairment charges; changes in last-in, first-out (“LIFO”) inventory reserves; gains/losses from the divestiture of businesses and other assets; acquisition, integration and divestiture-related costs; other income; derivative gains/losses; and other non-GAAP adjustments, if any, that may arise from time to time. Sonoco Adjusted EBITDA Margin is defined as Sonoco Adjusted EBITDA divided by Sonoco net sales. Pro forma Adjusted EBITDA is defined as pro forma net income attributable to Sonoco, excluding the same items as Sonoco Adjusted EBITDA, in each case calculated on a pro forma basis assuming Sonoco had owned Eviosys for the period presented. Pro forma Adjusted EBITDA Margin is defined as pro forma Adjusted EBITDA divided by pro forma net sales.
Sonoco’s non-GAAP financial measures are not calculated in accordance with, nor are they an alternative for, measures conforming to generally accepted accounting principles, and they may be different from similarly titled non-GAAP financial measures used by other companies. In addition, Sonoco’s non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Sonoco presents non-GAAP financial measures to provide investors with information to evaluate its operating results in a manner similar to how management evaluates business performance. In addition, these same non-GAAP financial measures are used in determining incentive compensation for the entire management team and in providing earnings guidance to the investing community. Sonoco consistently applies its non-GAAP financial measures and use them for internal planning and forecasting purposes, to evaluate its ongoing operations, and to evaluate the ultimate performance of management and each business unit against plans/forecasts. Sonoco’s pro forma non-GAAP financial measures are provided for illustrative purposes only and do not purport to represent the actual financial position and results of operations that would have been achieved had the Eviosys Acquisition and related financing transactions occurred on the dates indicated, and do not reflect adjustments for any anticipated integration costs, synergies, operating efficiencies, tax savings or cost savings. In addition, pro forma Adjusted EBITDA and pro forma Adjusted EBITDA Margin do not give effect to any potential divestitures by Sonoco,
including the potential divestitures of ThermoSafe, Sonoco’s leading temperature-assured packaging business, or TFP, its leading thermoformed and flexible packaging business, for which Sonoco has initiated reviews of strategic alternatives. On a standalone basis, ThermoSafe, which is part of the All Other group of businesses, had revenue of $283 million and an Adjusted EBITDA Margin in the low twenties for the year ended December 31, 2023. On a standalone basis, TFP, which Sonoco formed by integrating its flexible packaging and thermoforming businesses within its Consumer Packaging segment effective as of January 1, 2024, had revenue of $1.3 billion and an Adjusted EBITDA Margin in the mid-teens for the year ended December 31, 2023.
Material limitations associated with the use of such measures include that they do not reflect all period costs included in operating expenses and may not be comparable with similarly named financial measures of other companies. Furthermore, the calculations of these non-GAAP financial measures are based on subjective determinations of management regarding the nature and classification of events and circumstances that the investor may find material and view differently. To compensate for any limitations in such non-GAAP financial measures, the Company believes that it is useful in evaluating its results to review both GAAP information, which includes all of the items impacting financial results, and the related non-GAAP financial measures that exclude certain elements, as described above. Further, the Company does not, nor does the Company suggest that investors should, consider any non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Whenever reviewing a non-GAAP financial measure, investors are encouraged to review the related reconciliation to understand how it differs from the most directly comparable GAAP measure.
Reconciliation of GAAP to Non-GAAP Financial Measures
The following table reconciles Sonoco Adjusted EBITDA, Sonoco Adjusted EBITDA Margin, pro forma Adjusted EBITDA, and pro forma Adjusted EBITDA Margin for the year ended December 31, 2023 and the six months ended June 30, 2024 to net income attributable to Sonoco, Sonoco Net Income Margin, and pro forma net income attributable to Sonoco, and pro forma net income margin, respectively, for each of the periods presented. See Exhibit 99.3 to this Current Report on Form 8-K for more detailed information regarding the unaudited pro forma condensed combined financial information of Sonoco and Eviosys.
| | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, | | Six Months Ended June 30, | |
(Unaudited) | 2023 | | 2024 | | |
Dollars in thousands | Sonoco | Pro Forma | | Sonoco | Pro Forma | | |
| | | | | | | |
Net income attributable to Sonoco | $ | 474,959 | | $ | 367,842 | | | $ | 155,988 | | $ | 88,459 | | | |
Adjustments | | | | | | | |
Interest expense | 136,686 | | 395,971 | | | 60,860 | | 151,895 | | | |
Interest income | (10,383) | | (12,224) | | | (7,113) | | (8,708) | | | |
Provision for income taxes | 149,278 | | 112,087 | | | 44,667 | | 30,073 | | | |
Depreciation, depletion and amortization (a) | 340,988 | | 536,350 | | | 180,045 | | 277,192 | | | |
Non-operating pension costs | 14,312 | | 16,080 | | | 7,465 | | 8,289 | | | |
Net income attributable to noncontrolling interests | 942 | | 784 | | | 236 | | 687 | | | |
Restructuring/Asset impairment charges (b) | 56,933 | | 68,836 | | | 50,868 | | 57,377 | | | |
Changes in LIFO inventory reserves | (11,817) | | (11,817) | | | (987) | | (987) | | | |
Gain from divestiture of business and other assets | (78,929) | | (78,929) | | | (4,478) | | (4,478) | | | |
Acquisition, integration and divestiture-related costs (c) | 26,254 | | 87,070 | | | 27,930 | | 76,205 | | | |
Other income, net | (39,657) | | (39,657) | | | (5,867) | | (5,867) | | | |
Net gains from derivatives | (1,912) | | (1,912) | | | (3,771) | | (3,771) | | | |
Other adjustments (d) | 10,142 | | 14,675 | | | 1,124 | | 1,502 | | | |
Adjusted EBITDA | $ | 1,067,796 | | $ | 1,455,156 | | | $ | 506,967 | | $ | 667,868 | | | |
| | | | | | | |
Net Sales | $ | 6,781,292 | | $ | 9,372,001 | | | $ | 3,261,022 | | $ | 4,393,026 | | | |
Net Income Margin | 7.0 | % | 3.9 | % | | 4.8 | % | 2.0 | % | | |
Adjusted EBITDA Margin | 15.7 | % | 15.5 | % | | 15.5 | % | 15.2 | % | | |
(a) Pro forma depreciation, depletion and amortization expense includes estimated depreciation and amortization for Eviosys of $69,271 and $126,091, respectively, for the year ended December 31, 2023, and $34,446 and $62,701, respectively, for the six months ended June 30, 2024. See Notes 8(C) and 8(D) to Exhibit 99.3 to this Current Report on Form 8-K for more information on the estimated depreciation and amortization related to Eviosys.
(b) Restructuring and restructuring-related asset impairment charges are a recurring item as the Company’s restructuring programs usually require several years to fully implement, and the Company is continually seeking to take actions that could enhance its efficiency. Although recurring, these charges are subject to significant fluctuations from period to period due to the varying levels of restructuring activity, the inherent imprecision in the estimates used to recognize the impairment of assets and the wide variety of costs and taxes associated with severance and termination benefits in the countries in which the restructuring actions occur.
(c) Pro forma acquisition, integration and divestiture-related costs for the year ended December 31, 2023 include Sonoco historical costs and give further pro forma effect to (i) a $17,302 increase in cost of sales to reflect the estimated step up of finished goods and work in process inventory to fair value, (ii) a $38,514 increase in legal and professional expenses to reflect estimated Eviosys Acquisition-related transaction costs and (iii) a $5,000 increase in selling, general and administrative expenses to reflect estimated retention bonuses for certain Eviosys employees. Pro forma acquisition, integration and divestiture-related costs for the six months ended June 30, 2024 include Sonoco historical costs and give further pro forma effect to (i) $6,488 of legal and professional expenses incurred by Eviosys for costs related to the Eviosys Acquisition and (ii) $41,787 of selling, general and administrative expenses recognized by Eviosys to reflect estimated change in control bonuses for certain Eviosys employees.
(d) Pro forma other adjustments for the year ended December 31, 2023 include Sonoco historical costs and give further pro forma effect to $4,533 of costs associated with accounting for Eviosys’s operations in Turkey as highly inflationary under GAAP. Pro forma other adjustments for the six months ended June 30, 2024 include Sonoco historical costs and give further pro forma effect to $378 of costs associated with accounting for Eviosys’s operations in Turkey as highly inflationary under GAAP.